设计和合成AMPK激活器和GDF15诱导器
Meijian Zhang1,2,3, Andrea Bagán4, Donna Martínez4
1Department of Pharmacology, Toxicology and Therapeutic Chemistry, Institute of Biomedicine (IBUB), Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain.
Molecules (Basel, Switzerland)
|July 29, 2023
概括
研究人员开发了新的AMPK激活剂,以增加肥胖和2型糖尿病 (T2DM) 的生长分化因子15 (GDF15). 化合物21独特地提高了肝细胞中的GDF15蛋白水平,表现优于甲福林和BC1618.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
背景情况:
- 增长差异化因子15 (GDF15) 是肥胖和2型糖尿病 (T2DM) 的治疗标.
- AMP激活蛋白激酶 (AMPK) 激活剂正在研究它们对调节GDF15水平的潜力.
- 孤儿的ubiquitin E3联结酶子单元蛋白Fbxo48抑制剂,BC1618,作为新型化合物开发的结构基础.
研究的目的:
- 设计,合成和评估新的AMPK激活剂,以提高它们对GDF15.15的调节能力.
- 与现有的药物如甲福明和BC1618.18相比,识别具有提高GDF15mRNA和蛋白质水平的强效化合物.
- 研究新型化合物对人类肝细胞中AMPK酸化和GDF15表达的影响.
主要方法:
- 基于BC1618结构的一系列新型化合物的合成.
- 在人体Huh-7肝细胞中合成的化合物的体外药理学评估.
- 测量GDF15mRNA和蛋白质水平,并评估AMPK酸化.
主要成果:
- 化合物BC1618在增加GDF15mRNA水平方面显示出比甲福明更高的功效.
- 合成和评估了35种新型化合物,其中21种化合物与BC1618.18相比显示出优异的GDF15mRNA上调.
- 化合物21独特地增加了GDF15蛋白水平,同时增加了AMPK酸化,使其与甲福明和BC1618.
结论:
- 化合物21具有独特的能力,可以在人类肝细胞中提高GDF15蛋白水平.
- 开发的化合物,特别是21化合物,代表了针对代谢障碍中的GDF15的有希望的治疗候选者.
- 对21化合物的机制和疗效进行进一步的研究是有必要的,因为它可能在肥胖和T2DM治疗中得到应用.
关键词:
(1-二zylamino-3-phenoxy) -2-ol -2-ol -2-ol -1-dibenzylamino-3-phenoxy) -2-ol -2-ol -2-ol -1-dibenzylamino-3-phenoxy) -2-ol -2-ol -2-ol -1-dibenzylamino-3-phenoxy -1-dibenzylamino-3-phenoxy -1-dibenzylamino-3-phenoxy -2-ol -2-ol -1-dibenzylamino-3-phenoxy -2-ol -1-dibenzylamino-3-phenoxy -1-dibenzylamino-3-phenoxy) -2-ol -2-ol -2-ol -2-ol -1-dibenzylamino-3-phenoxy -1-dibenzylamino-3-phenoxy -1-dibenzylamino-3-phenoxy -2-ol -1-propan-2-ol -2-ol -2-ol -2-ol -2--2-这就是AMPKK.BC1618 BC1618 是一个在GDF15中,GDF15是GDF15中的一个.相关概念视频
cAMP-dependent Protein Kinase Pathways
6.4K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.4K
GPCRs Regulate Adenylyl Cylase Activity
5.7K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.7K
Amplifying Signals via Enzymatic Cascade
8.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K
Structure-Activity Relationships and Drug Design
770
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
770
GPCR Desensitization
6.1K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.1K
Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358


